Plasma protein therapies: current and future perspectives

Farrugia, Albert; P, Robert

doi:10.1016/j.beha.2005.01.002

Cited by 30 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Worldwide, people with haemophilia have been the primary users of plasma products, as they are often prescribed coagulation factors on a long-term basis. However, global demand for plasma is today driven by the expansion of immunoglobulin therapies for diverse indications (Farrugia, 2006). …”

Section: Demand In the Blood Economymentioning

confidence: 99%

Revaluing donor and recipient bodies in the globalised blood economy: Transitions in public policy on blood safety in the United Kingdom

2013

View full text Add to dashboard Cite

The clinical use of blood has a long history, but its apparent stability belies the complexity of contemporary practices in this field. In this article, we explore how the production, supply and deployment of blood products are socially mediated, drawing on theoretical perspectives from recent work on ‘tissue economies’. We highlight the ways in which safety threats in the form of infections that might be transmitted through blood and plasma impact on this tissue economy and how these have led to a revaluation of donor bodies and restructuring of blood economies. Specifically, we consider these themes in relation to the management of recent threats to blood safety in the United Kingdom. We show that the tension between securing the supply of blood and its products and ensuring its safety may give rise to ethical concerns and reshape relations between donor and recipient bodies.

show abstract

Section: Demand In the Blood Economymentioning

confidence: 99%

Revaluing donor and recipient bodies in the globalised blood economy: Transitions in public policy on blood safety in the United Kingdom

2013

View full text Add to dashboard Cite

show abstract

“…All these technologies in various combination coupled with various virus inactivating procedures have given us replacement therapy for a host of coagulation disorders [52] specific immunoglobulins for prevention of certain diseases, antithrombin III, Protein C concentrates for use in thrombophilic conditions and intravenous immunoglobulins for its use in various autoimmune haematological disorders (e.g. ITP, acquired factor VIII deficiency) and in case of humoral immunodeficiencies either congenital and acquired as in case of chronic lymphatic leukaemia or for certain periods after allogeneic haematopoietic stem cell transplantation [53].…”

Section: Fractionated Plasma Proteins and Other Proteinsmentioning

confidence: 99%

Advances in Haematological Pharmacotherapy in 21st Century

Ghosh¹,

Ghosh²

2010

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Last quarter of twentieth century and the first 10 years of 21st century has seen phenomenal development in haematological pharmacotherapy. Tailor made chemotherapeutic agents, vast array of monoclonal antibodies, epigenetic modifiers, growth factors for red cells white cells and platelets, peptidomimetics as growth factors, newer thrombin inhibitors, safer plasma derived protein molecules, recombinant molecules, newer immunomodulators, enzyme replacement therapy and above all a plethora of targetted molecules targeting innumerable pathways involved in cell division, growth, proliferation and apoptosis has given immense number of clinically usable molecules in the hand of modern haematologists to treat diverse hitherto untreatable haematological disorders effectively. In addition many old molecules are finding newer uses in diverse fields, thalidomide as an antiangiogenic molecule is a prime example of this genre. Present overview has tried to capture this rapidly evolving area in a broad canvas without going into details of indications and contraindications of the use of various drugs.

show abstract

“…Further, for any given company, manufacturing costs can be managed best by large‐scale fractionation above 1,000,000 L of plasma per year. The latter is one of the driving factors behind consolidation within the fractionation industry [63]. While increasing the volume of fractionated plasma would be expected to both meet increased IgG demand and reduce manufacturing costs, the cost‐implications are not linear as demand for the co‐fractionated products, such as albumin and coagulation factors, has to rise by similar magnitudes as the IgG demand to ensure economically reasonable cost sharing and to avoid wasting of precious proteins of human origin [64].…”

Section: Factors Which May Influence Igg Availability and Cost In Thementioning

confidence: 99%

Immunoglobulin G for the Treatment of Chronic Pain: Report of an Expert Workshop

et al. 2014

View full text Add to dashboard Cite

show abstract

Plasma protein therapies: current and future perspectives

Cited by 30 publications

References 22 publications

Revaluing donor and recipient bodies in the globalised blood economy: Transitions in public policy on blood safety in the United Kingdom

Revaluing donor and recipient bodies in the globalised blood economy: Transitions in public policy on blood safety in the United Kingdom

Advances in Haematological Pharmacotherapy in 21st Century

Immunoglobulin G for the Treatment of Chronic Pain: Report of an Expert Workshop

Contact Info

Product

Resources

About